Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01358695 · ClinicalTrials.gov registry record · Phase 2

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

A Phase 2 study, sponsored by Anterios.

Completed
Registry status
Phase 2
Development phase
111
Enrollment target

NCT01358695: Completed Phase 2 study, sponsored by Anterios.

NCT01358695 is a Phase 2 study that has completed, run by Anterios. The registered enrollment target is 111 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01358695, a Phase 2 study, has completed, sponsored by Anterios.

COMPLETED
Registry status
Phase 2
Development phase
111 participants
Enrollment target

Study Summary

The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.

Primary Outcome

Wrinkle scale with definitions of severity

Interventions

  • BIOLOGICAL Botulinum Toxin Type A
  • BIOLOGICAL ANT-1207
  • BIOLOGICAL Botulinum Toxin, Type A

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2011-05
Est. Completion 2012-05
Phase Phase 2
Anterios

5 total trials

What the finished NCT01358695 record still lists

NCT01358695 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).

The record links to 0 conditions, and to 3 interventions - of which Botulinum Toxin Type A is the first listed.

NCT01358695 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01358695 about?

NCT01358695 is a clinical study titled "Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet". The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.

What is the current status of trial NCT01358695?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2011-05. Estimated completion is 2012-05.

What interventions are being tested in trial NCT01358695?

The interventions under investigation include: Botulinum Toxin Type A (BIOLOGICAL), ANT-1207 (BIOLOGICAL), Botulinum Toxin, Type A (BIOLOGICAL).

Who is sponsoring clinical trial NCT01358695?

This trial is sponsored by Anterios, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01358695's enrollment target sits among peer trials

111 632nd of 2000 higher than 1,369 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03875716 · 111 participants · NA

    Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

  • NCT04693468 · 111 participants · Phase 1

    Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

  • NCT05263050 · 111 participants · Phase 2

    Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

  • NCT05600842 · 111 participants

    De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01358695, the US trial registry maintained by the National Library of Medicine. NCT01358695 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.